Extended MHRA licence for elinzanetant in breast cancer patients The Medicines and Healthcare products Regulatory Agency (MHRA) has extended the licence for elinzanetant, an NK1/NK3 receptor antagonist, for the treatment of moderate to severe vasomotor symptoms in women receiving adjuvant endocrine therapy for breast cancer. This is the first medicine specifically licensed for this [...]
New WHC Fact Sheet: Hormone blood tests in the menopause transition Women's Health Concern (WHC), the patient arm of the British Menopause Society (BMS), has published a new fact sheet examining the role of hormone blood tests in the menopause transition. The resource builds on the BMS Tool for Clinicians on the measurement of [...]
The British Menopause Society has published a new BMS Tool for Clinicians: Menopausal 'brain fog' or dementia? – a practical guide for clinicians. Cognitive symptoms such as memory lapses, difficulty concentrating, and mental fatigue, collectively known as 'brain fog', are frequently reported during perimenopause and menopause, causing patient distress and sometimes prompting concern about [...]
A UCL doctoral research project is mapping current clinical practice around cognitive symptoms in menopause. Findings will inform future guidelines and feed into ongoing British Menopause Society tool development. UCL doctoral student Seren Alaeddinoglu is conducting a study entitled: Screening for menopause-related 'brain fog' in primary care settings. The project has two primary objectives: [...]
A large multinational cohort study published in Lancet Obstetrics, Gynaecology & Women's Health (Marschner et al., 2026) provides important evidence on the association between premature and early menopause and major cardiovascular events across diverse regions and ethnic groups. The Prospective Urban Rural Epidemiologic (PURE) study followed 111,619 women across 26 countries over a median [...]
Following a BMS consensus review of current evidence, four key clinical resources have been updated to ensure consistency in the tables detailing approximate equivalent estrogen doses and the recommended stand-alone progestogen doses per licensed estrogen dose.
The British Menopause Society (BMS) board of trustees has made the decision to review the BMS menopause specialist programme and, as a result, specialist registration is currently suspended. As the review progresses, the BMS will continue to educate healthcare professionals (HCPs). Completion of the BMS Advanced Certificate in the Principles & Practice of Menopause [...]
Appointment supports continued focus on evidence-based communication in menopause care. The British Menopause Society (BMS) has appointed Emily Josif as its new Communications Manager. The role will support the Society’s ongoing work to provide clear, evidence-based information to healthcare professionals and stakeholders involved in menopause and post reproductive health. Emily brings experience in strategic [...]
The British Menopause Society welcomes today’s announcement that women across the country will be better heard and served under plans set out in the renewed Women’s Health Strategy. Read the full announcement on the gov.uk website: Women's voices to be at the heart of renewed health strategy.
A new treatment option for menopausal hot flushes and night sweats can now be used in the NHS when HRT is not suitable, with around 500,000 eligible to benefit. Fezolinetant is recommended to treat moderate to severe symptoms in final draft NICE guidance published today. Hot flushes and night sweats can hugely affect daily life by disrupting sleep, concentration, relationships and the ability to [...]
